MA37880B1 - Formulation transdermique contenant des inhibiteurs de cox - Google Patents

Formulation transdermique contenant des inhibiteurs de cox

Info

Publication number
MA37880B1
MA37880B1 MA37880A MA37880A MA37880B1 MA 37880 B1 MA37880 B1 MA 37880B1 MA 37880 A MA37880 A MA 37880A MA 37880 A MA37880 A MA 37880A MA 37880 B1 MA37880 B1 MA 37880B1
Authority
MA
Morocco
Prior art keywords
formulation containing
transdermal formulation
cox inhibitors
containing cox
preparation
Prior art date
Application number
MA37880A
Other languages
English (en)
Other versions
MA37880A1 (fr
Inventor
Endre Mikulásik
Tamás Spaits
Sinka Ágota Szakályné
Original Assignee
Egis Gyógyszergyár Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37880(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Egis Gyógyszergyár Zrt filed Critical Egis Gyógyszergyár Zrt
Publication of MA37880A1 publication Critical patent/MA37880A1/fr
Publication of MA37880B1 publication Critical patent/MA37880B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions de gel appropriées pour l'administration topique d'un composé actif présentant une faible solubilité et une propriété de pénétration cutanée, par exemple, de composés inhibiteurs de cox-2, leurs procédés de préparation et leurs méthodes d'utilisation pour le traitement d'indications pouvant être traitées au moyen du composé actif.
MA37880A 2012-07-31 2013-07-31 Formulation transdermique contenant des inhibiteurs de cox MA37880B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/562,686 US10045935B2 (en) 2012-07-31 2012-07-31 Transdermal formulation containing COX inhibitors
PCT/HU2013/000080 WO2014020366A1 (fr) 2012-07-31 2013-07-31 Formulation transdermique contenant des inhibiteurs de cox

Publications (2)

Publication Number Publication Date
MA37880A1 MA37880A1 (fr) 2016-02-29
MA37880B1 true MA37880B1 (fr) 2016-09-30

Family

ID=49231593

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37880A MA37880B1 (fr) 2012-07-31 2013-07-31 Formulation transdermique contenant des inhibiteurs de cox

Country Status (40)

Country Link
US (2) US10045935B2 (fr)
EP (1) EP2879664B1 (fr)
JP (3) JP6374383B2 (fr)
KR (1) KR20150032892A (fr)
CN (1) CN104768530B (fr)
AU (2) AU2013298294A1 (fr)
BR (1) BR112015002041B1 (fr)
CA (1) CA2880442C (fr)
CL (1) CL2015000240A1 (fr)
CO (1) CO7240432A2 (fr)
CR (1) CR20150044A (fr)
CU (1) CU24246B1 (fr)
CY (1) CY1123805T1 (fr)
DK (1) DK2879664T3 (fr)
EA (1) EA033950B1 (fr)
EC (1) ECSP15003613A (fr)
ES (1) ES2841992T3 (fr)
GE (1) GEP20176630B (fr)
HK (1) HK1211490A1 (fr)
HR (1) HRP20210008T1 (fr)
HU (1) HUE053418T2 (fr)
IL (1) IL236988B (fr)
IN (1) IN2015DN01329A (fr)
LT (1) LT2879664T (fr)
MA (1) MA37880B1 (fr)
MD (1) MD20150018A2 (fr)
MX (1) MX361697B (fr)
NI (1) NI201500007A (fr)
NZ (1) NZ704567A (fr)
PE (1) PE20150755A1 (fr)
PH (1) PH12015500200A1 (fr)
PL (1) PL2879664T3 (fr)
PT (1) PT2879664T (fr)
RS (1) RS61326B1 (fr)
SG (1) SG11201500734SA (fr)
SI (1) SI2879664T1 (fr)
TN (1) TN2015000037A1 (fr)
UA (1) UA116636C2 (fr)
WO (1) WO2014020366A1 (fr)
ZA (1) ZA201500744B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN108904812A (zh) * 2018-08-27 2018-11-30 邛崃市医疗中心医院 以卡波姆协同透皮剂的高透皮性防治肩周炎的外用药物
CN114601789B (zh) * 2022-03-29 2024-03-26 辽宁方诺生物科技有限公司 一种塞来昔布凝胶剂及其制备方法和应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998973A (en) 1975-04-07 1976-12-21 R. T. Vanderbilt Company, Inc. Thickening composition
FR2339392A1 (fr) 1976-02-02 1977-08-26 Oreal Compositions contenant des derives du silicium
GB2050160A (en) 1979-04-10 1981-01-07 Nottage H C Cosmetic protective cream
FR2471778A1 (fr) 1979-12-21 1981-06-26 Oreal Procede de traitement des cheveux en vue d'ameliorer leur aspect a l'aide d'une composition contenant un hydrolysat de lactalbumine
EP0126138A1 (fr) 1982-11-04 1984-11-28 Redken Laboratories Inc. Preparation cosmetique
GB8320366D0 (en) 1983-07-28 1983-09-01 Gillette Co Hair relaxing compositions
GB8421112D0 (en) 1984-08-20 1984-09-26 Unilever Plc Pyroglutamic acid esters
GB8600568D0 (en) 1986-01-10 1986-02-19 Gillette Co Hair relaxing compositions
US4831023A (en) 1986-06-27 1989-05-16 Thames Pharmacal Co., Inc. Water washable vehicles for topical use
US4837019A (en) 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
DE3805744C2 (de) 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
DE3714140A1 (de) 1987-04-28 1988-11-10 Lohmann Therapie Syst Lts Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH02145512A (ja) 1988-11-26 1990-06-05 Shin Etsu Chem Co Ltd 被膜形成型外用剤
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
DE4131678A1 (de) 1991-04-13 1992-10-15 Beiersdorf Ag Stabile multiple emulsionen
AU2259692A (en) 1991-07-03 1993-02-11 Sano Corporation Composition and method for transdermal delivery of diclofenac
US5300286A (en) 1992-07-14 1994-04-05 Dow Corning Corporation Silicone emulsion for personal care application
US5210103A (en) 1992-09-02 1993-05-11 Basf Corporation Volatile silicone oil-blown integral skin foam
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9315755D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
FR2709131B1 (fr) 1993-08-18 1995-11-10 Cilag Laboratoire Dispositif de distribution d'une substance thérapeutique ou cosmétique dont le véhicule inerte est un polydiorganosiloxane volatil, et composition destinée à être utilisée dans le dispositif.
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5620692A (en) 1993-12-23 1997-04-15 Nurture, Inc. Oat oil compositions with useful cosmetic and dermatological properties
GB9404248D0 (en) 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
IL116539A (en) 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2738565B1 (fr) 1995-09-13 1997-11-28 Dior Christian Parfums Produits extraits d'une plante du genre commiphora, en particulier de la plante commiphora mukul, et extraits en contenant et leurs applications notamment en cosmetique
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU2456097A (en) 1996-05-21 1997-12-09 Dermasciences, Inc. Topical barrier composition containing silicone and bentonite
GB9611167D0 (en) 1996-05-29 1996-07-31 Glaxo Group Ltd Medicaments
RU2185144C2 (ru) 1996-06-28 2002-07-20 Унилевер Н.В. Жидкая композиция антиперспиранта/дезодоранта
FR2751874B1 (fr) 1996-08-02 1998-08-28 Sederma Sa Nouvelles compositions cosmetiques pour embellir et eclaircir la peau
GB9618974D0 (en) 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
US5756109A (en) 1996-09-27 1998-05-26 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing geranyl geraniol and retinol or retinyl esters
US5747051A (en) 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19700913C2 (de) 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
FR2763842B1 (fr) 1997-05-27 2000-09-15 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant des derives de threonine ou de serine
FR2768335B1 (fr) 1997-09-12 2000-03-03 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant une association d'extrait d'algue et d'exopolysaccharide
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
DE19750029A1 (de) 1997-11-12 1999-05-20 Merck Patent Gmbh Stabile kosmetische Formulierung enthaltend Butylmethoxydibenzoylmethan
DE19750030A1 (de) 1997-11-12 1999-05-20 Merck Patent Gmbh Lichtstabile kosmetische Formulierung enthaltend Butylmethoxydibenzoylmethan
US6187300B1 (en) 1997-12-17 2001-02-13 The Procter & Gamble Company Antiperspirant cream compositions having improved wash-off and antiperspirant efficacy
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US20060015058A1 (en) 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
MXPA01000973A (es) 1998-08-03 2002-06-04 Epigenesis Pharmaceuticals Inc Un nuevo agente analgesico antiinflamatorio y de cicatrizacion de heridas.
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
GB9828379D0 (en) 1998-12-22 1999-02-17 Unilever Plc Skin care composition
US6007829A (en) 1998-12-17 1999-12-28 Cheesebrough-Pond's Usa Co. Cosmetic skin care compositions containing succinate compounds
FR2791887B1 (fr) 1999-04-06 2004-04-23 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques renfermant des extraits vegetaux de pinus lambertania contre la secheresse cutanee de toute origine
PT3146969T (pt) 1999-04-23 2018-10-18 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
KR100319473B1 (ko) 1999-08-24 2002-01-05 김강권 실크아미노산 수용액을 주재로한 아이스크림류의 제조방법
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
FR2802097B1 (fr) 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US6361806B1 (en) 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
CA2406024C (fr) 2000-03-17 2012-05-22 Avocet Polymer Technologies, Inc. Procedes permettant d'ameliorer la taille et l'aspect d'une blessure
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6589557B2 (en) 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
DE10032132A1 (de) 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
IN191090B (fr) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE10042411A1 (de) 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
GB0027769D0 (en) 2000-11-14 2000-12-27 Unilever Plc Cosmetic method of treating skin
GB0028355D0 (en) 2000-11-21 2001-01-03 Unilever Plc Cosmetic method of treating skin
GB0028706D0 (en) 2000-11-24 2001-01-10 Unilever Plc Cosmetic composition
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
JP2004532871A (ja) 2001-05-31 2004-10-28 ファルマシア・コーポレーション 皮膚浸透性シクロオキシゲナーゼ−２選択的阻害組成物
GB0119583D0 (en) 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
CN1606445A (zh) * 2001-10-23 2005-04-13 兰贝克塞实验室有限公司 用于局部传递环加氧酶－2酶抑制剂的药物组合物的制备方法
US20030104019A1 (en) 2001-11-01 2003-06-05 Mcculloch Laura Composition for reducing enzymatic irritation to skin
DE10164531A1 (de) 2001-12-31 2003-07-17 Pharmatech Gmbh Zubereitung zur Oberflächenanästhesie der Haut
US6838078B2 (en) 2002-01-16 2005-01-04 3M Innovative Properties Company Film-forming compositions and methods
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
EP1490030B2 (fr) 2002-03-20 2010-07-14 Elan Pharma International Limited Compositions nanoparticulaires d'inhibiteurs d'angiogenese
US20030199584A1 (en) 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20030199537A1 (en) 2002-04-18 2003-10-23 Cannon John B. Polymorph of a pharmaceutical
JP2004075592A (ja) 2002-08-14 2004-03-11 Masahiko Abe 非イオン性ベシクルおよびその利用
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
US20060241175A1 (en) 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
EP1635771A2 (fr) 2003-04-18 2006-03-22 MERCK PATENT GmbH Formulations cosmétiques comprenant des pigments antimicrobiens
ITRM20030204A1 (it) 2003-04-29 2004-10-30 Provincia Italiana Della Congregazi One Dei Figli Formulazione dermatologica.
FR2854897B1 (fr) 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
EP1627644A4 (fr) 2003-05-23 2012-01-18 Hisamitsu Pharmaceutical Co Preparation administree par voie percutanee externe et contenant une substance medicamenteuse anti-inflammatoire non steroidienne et un inhibiteur de production d'interleukine-1$g(a)
WO2005000248A2 (fr) 2003-06-25 2005-01-06 Geron Corporation Compositions et procedes de traitement de la peau
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005007129A2 (fr) 2003-07-17 2005-01-27 Angiotech International Ag Formulations topiques a elements bioactifs
JP2007508243A (ja) 2003-08-04 2007-04-05 フォーミックス エルティーディー． 両親媒性コポリマーゲル化剤を含む泡坦体
EP1656097A1 (fr) 2003-08-07 2006-05-17 The Procter & Gamble Company Emulsions eau dans l'huile
WO2005044227A1 (fr) 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Compositions pharmaceutiques topiques
WO2005046600A2 (fr) 2003-11-07 2005-05-26 Nexmed Holdings, Inc. Systeme d'application de tulobuterol transdermique, procede et composition correspondants
FR2862871B1 (fr) 2003-12-01 2008-05-30 Camet Anne Dupouy Composition cosmetique anti-pollution
US20050255131A1 (en) 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
US7662855B2 (en) 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US20050255133A1 (en) 2004-05-11 2005-11-17 Alpharx Inc. Topical composition for acne treatment
US20070264319A1 (en) 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
US20070267035A1 (en) 2004-09-07 2007-11-22 Henkel Kommanditgesellschaft Auf Aktien Composition and Method for the Smoothing of Fibres Containing Keratin
CA2580659C (fr) 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroide ayant une faible absorption systemique
TW200616589A (en) 2004-10-08 2006-06-01 Noven Pharma Transdermal delivery of drugs based on crystal size
WO2006091297A2 (fr) 2005-02-23 2006-08-31 The Regents Of The University Of California Molecules ameliorant l'administration percutanee et methodes de decouverte associees
WO2006138035A1 (fr) 2005-06-13 2006-12-28 Dow Corning Corporation Vehicule pour l'administration d'agents pharmaceutiques solubles lipidiques topiques
CA2618993A1 (fr) 2005-08-13 2007-02-22 Collegium Pharmaceutical, Inc. Administration topique a l'aide d'un fluide porteur
WO2007051596A1 (fr) 2005-11-03 2007-05-10 Dsm Ip Assets B.V. Nouveaux biotinates de rétinyle et applications
KR100658436B1 (ko) 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
EP1978997A1 (fr) 2005-12-22 2008-10-15 Apollo Life Sciences Limited Livraison transdermale d'agents pharmaceutiques
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
HUP0900072A2 (hu) 2009-02-06 2010-09-28 Egis Gyogyszergyar Nyilvanosan Transzdermális gyógyszerkészítmények
EP2178519B1 (fr) 2007-07-13 2012-04-25 Bend Research, Inc. Nanoparticules comprenant un polymère non ionisable et un polymère cellulosique anionique
WO2009031318A1 (fr) 2007-09-05 2009-03-12 Kowa Co., Ltd. Préparation pour une application externe comprenant un agent analgésique/anti-inflammatoire
WO2009063367A1 (fr) 2007-11-15 2009-05-22 Pfizer Products Inc. Formes galéniques comprenant du célécoxib permettant un soulagement de la douleur à la fois rapide et prolongé
WO2010047831A1 (fr) 2008-10-23 2010-04-29 Nycomed Us Inc. Formulations de gel de métronidazole stables
KR20110127687A (ko) 2009-03-11 2011-11-25 코와 가부시키가이샤 진통·항염증제 함유 외용제
WO2010103845A1 (fr) * 2009-03-11 2010-09-16 興和株式会社 Préparation externe contenant un analgésique/anti-inflammatoire
EP2575813A1 (fr) * 2010-05-28 2013-04-10 Nuvo Research Inc. Formulation topique d'étoricoxib
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Also Published As

Publication number Publication date
CY1123805T1 (el) 2022-05-27
BR112015002041B1 (pt) 2022-11-16
ZA201500744B (en) 2016-10-26
HUE053418T2 (hu) 2021-07-28
EP2879664A1 (fr) 2015-06-10
JP2022022374A (ja) 2022-02-03
EA033950B1 (ru) 2019-12-12
CN104768530B (zh) 2018-08-21
JP2018100299A (ja) 2018-06-28
PT2879664T (pt) 2021-01-13
WO2014020366A1 (fr) 2014-02-06
LT2879664T (lt) 2021-01-25
PL2879664T3 (pl) 2021-06-28
HK1211490A1 (en) 2016-05-27
IL236988A0 (en) 2015-03-31
DK2879664T3 (da) 2021-01-11
KR20150032892A (ko) 2015-03-30
US20150231247A1 (en) 2015-08-20
NI201500007A (es) 2015-06-10
CA2880442C (fr) 2020-10-27
NZ704567A (en) 2018-02-23
CO7240432A2 (es) 2015-04-17
JP7210833B2 (ja) 2023-01-24
PH12015500200A1 (en) 2015-03-16
GEP20176630B (en) 2017-02-27
UA116636C2 (uk) 2018-04-25
MA37880A1 (fr) 2016-02-29
CU24246B1 (es) 2017-02-02
MX2015001387A (es) 2015-09-16
MD20150018A2 (ro) 2015-07-31
SG11201500734SA (en) 2015-02-27
RS61326B1 (sr) 2021-02-26
AU2018202875B2 (en) 2019-12-12
CA2880442A1 (fr) 2014-02-06
PE20150755A1 (es) 2015-06-07
JP7384885B2 (ja) 2023-11-21
ES2841992T3 (es) 2021-07-12
AU2013298294A1 (en) 2015-02-26
CL2015000240A1 (es) 2015-09-11
CN104768530A (zh) 2015-07-08
IN2015DN01329A (fr) 2015-07-03
HRP20210008T1 (hr) 2021-03-05
CU20150010A7 (es) 2015-08-27
BR112015002041A2 (pt) 2017-07-04
AU2018202875A1 (en) 2018-05-17
US10045935B2 (en) 2018-08-14
JP2015523408A (ja) 2015-08-13
EP2879664B1 (fr) 2020-10-07
US20140037738A1 (en) 2014-02-06
MX361697B (es) 2018-12-14
EA201590269A1 (ru) 2015-05-29
JP6374383B2 (ja) 2018-08-15
ECSP15003613A (es) 2015-12-31
IL236988B (en) 2019-06-30
CR20150044A (es) 2015-07-01
SI2879664T1 (sl) 2021-02-26
TN2015000037A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
MX2022002465A (es) Inhibidores de kras g12d.
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA37880B1 (fr) Formulation transdermique contenant des inhibiteurs de cox
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA38483A1 (fr) Inhibiteurs de l'ido
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
NZ706739A (en) Substituted benzene compounds
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
TN2014000195A1 (fr) 2-thiopyrimidinones
TR201908247T4 (tr) Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
TR201902125T4 (tr) Si̇stemi̇k olarak etki̇ eden akti̇f ajanlari i̇çeren parazi̇ti̇si̇dal oral veteri̇nerli̇ğe ai̇t bi̇leşi̇mler, bunlarin yöntemleri̇ ve kullanimlari
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA33457B1 (fr) L-sérine pour son utilisation en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
GB2476446A (en) Topical treatment of skin infection
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
DE602006013826D1 (de) Zusammensetzungen zur behandlung von systemischer mastocytose